

April 22, 2021

## First Topline Contraction in Five Years

### **Subdued Demand Weighs on Product Sales**

CADBURY's 2020FY performance mirrored the impact of the slowdown in economic activities following the challenges posed by the coronavirus pandemic, and sustained pressure on consumer wallets. The company recorded a decline in all its product segments, hence, revenue dipped by 9.97% YoY to NGN35.41bn (vs. NGN39.33bn in 2019FY). Notably, last year's revenue decline represents the company's first topline contraction since 2015FY. Refreshment beverage sales which historically contributes c. 58.22% to overall revenue slumped by 6.71% YoY, while sales of Confectionary products also fell by 4.46% YoY. Intermediate cocoa products – the company's major source of export earnings – plunged significantly (-39.54% YoY to NGN2.83bn, from NGN4.69bn in the prior year), due to challenges associated with the land border closure. We envisage a rebound in cocoa exports flowing from the Federal Government's decision to reopen the country's land borders in December 2020. For local demand, we posit that a gradual recovery of economic activities and sustained improvement in the company's route to market strategy would support domestic sales over 2021FY. Hence, we forecast a 11.50% growth in revenue to NGN39.48bn (vs. NGN35.41bn in 2020FY).

#### **Cost Management Fails to Save Bottomline**


Despite the 6.31% increase in raw material costs during the year, total production costs fell by 4.82% to NGN29.51bn (vs. NGN31.00bn in 2019FY). This moderation however failed to reflect in the company's cost to sales ratio, which climbed to 83.34% (from 78.83% in 2019FY). Hence, gross margin also contracted to 16.66% (vs. 21.17%). The company slowed down on advertising and sales promotion (-40.90% YoY), and recorded declines in both technical services (-55.83% YoY) and office consumable expense (-38.65% YoY) - which eventually drove down Opex by 18.88% to NGN5.73bn. The moderation in operating expenses reveals the company's efforts at containing costs amidst spiraling inflation and COVID-19 induced disruption to its operations.

While gains from the disposal of property, plant, and equipment (totaling NGN67.66mn) provided some support, operating profits however dropped to NGN281.82mn, from NGN1.35bn in the previous year. PBT and PAT also plummeted by 73.48% and 12.98% YoY, respectively. Profit after tax (PAT) settled at NGN931.82mn (implied EPS: NGN0.50). In 2021FY, the drive to push volumes and our expectation of higher raw material prices inform our 5.52% uptick in production costs. We also considered the likelihood of the CBN's plan to include sugar (and wheat) in its FX restriction list - a move that could translate to a climb in production costs, crystallizing in the near to midterm. After carefully considering these factors, we forecast 2021FY net income would settle at NGN1.10bn – 18.81% higher than the NGN931.83mn recorded in 2020FY.

### Fresh Debt Supports Liquidity

While the company has maintained a low levered balance sheet over the years, it obtained NGN3.45bn finance facility towards the end of 2020FY, to meet its importation needs. As a result, its cash balance improved by 150.96% to NGN11.11bn, while total debt ratio expanded to 0.10x. Cash and quick ratios also showed improvement from previous levels, ticking up to 0.77x and 1.05x (vs. 0.45x and 0.92x respectively), signaling better liquidity to cover short-term obligations.

Company	CADBURY
Valuation	
EPS	0.50
BVPS	7.21
P/E	16.33x
P/BV	1.12x
Target PE	13.84x
Dec-2021 Exp. EPS	0.59
Dec 2021 Target price	8.16
Current Price	7.80
Up/Downside Potential	+4.60%
Ratings	HOLD
Key metrics	
ROE	6.88%
ROA	2.81%
Net margin	2.63%
Asset Turnover	1.14
Leverage	2.45x
Share/Share Price	
Statistics	
Yr Hi	NGN10.80
Yr Lo	NGN8.00
YTD return	-25.93%
Beta	0.91
Adjusted Beta	0.94
Shares outstanding	1.88bn
Market cap [NGN]	15.21bn
Financial year end	December
Most Recent Period	
(MRP)	2020FY





April 22, 2021

### Recommendation

We project a 2021FY expected EPS of NGN0.59 and a target PE of 13.84x. This yields a price target of NGN8.16, and an implied 4.60% upside potential based on the closing price on April 22<sup>nd</sup>,2021. Hence, we rate the ticker a **HOLD**.

**Chart 1: Sensitivity Analysis** 

Sensitivity Analysis of Dec-2021 Target Price to key model inputs					Min	7.68		
		EPS				Max	8.66	
	8.16	0.57	0.58	0.59	0.60	0.61		
	13.43x	7.68	7.80	7.91	8.03	8.15		
Toward DE	13.63x	7.80	7.92	8.04	8.16	8.28		
Target PE	13.84x	7.91	8.04	8.16	8.28	8.40		
	14.05x	8.03	8.16	8.28	8.41	8.53		
	14.26x	8.15	8.28	8.40	8.53	8.66		

Financial Highlights (NGN' mn) Cadbury Nigeria Plc. 2020FY Au	Financial Highlights (NGN' mn) Cadbury Nigeria Plc. 2020FY Audited Results					
Profit & Loss Account	2020FY	2019FY	y/y Growth			
Revenue	35,407	39,327	-9.97%			
Cost of Sales	29,508	31,001	-4.82%			
Gross Profit	5,899	8,326	-29.15%			
Investment income	127	185	-31.21%			
Other income	108	87	24.00%			
Operating Expense	5,725	7,058	-18.88%			
Finance Cost	1	1	5.72%			
PBT	408	1,539	-73.48%			
PAT	932	1,071	-12.98%			
Balance Sheet	2020FY	2019FY				
Inventories	5,244	6,063	-13.50%			
Trade and other Receivables	3,856	4,530	-14.88%			
Cash and bank	11,116	4,429	150.96%			
Property, Plant and Equipment	12,759	13,477	-5.33%			
Other Assets	236	303	-22.17%			
Total Assets	33,211	28,802	15.31%			
Shareholders' fund	13,550	13,566	0.12%			
Trade and Other Payables	10,910	9,617	-11.85%			
Tax Liabilities	113	283	150.90%			
Total Liabilities	19,661	15,236	29.05%			



April 22, 2021

## **Contact Information**

**Brokerage and Retail Services** 

topeoludimu@meristemng.com (+234 905 569 0627) olatunjifaniyi@meristemng.com (+234 803 446 3118)

**Investment Banking/Corporate Finance** 

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

Wealth Management

contact@meristemng.com

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com

Tel: +234 01 738 9948

Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783)

www.meristemregistrars.com Tel: +23401-280 9250

**Trust Services** 

damilolahassan@meristemng.com (+234 803 613 9123) crmwealth@meristemng.com

**Group Business Development** 

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 3942967) emekaikpechukwu@meristemng.com (+234 803 791 5731) info@meristemng.com

Client Services

adefemitaiwo@meristemng.com (+234 803 694 3034) blessingogwuche@meristemng.com (+234 706 896 5173)

car@meristemng.com

Investment Research

ahmedjinad@meristemng.com (+234 809 183 9487)

research@meristemng.com

**Corporate websites:** www.meristemwealth.com www.meristemng.com www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com FactSet: www.factset.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

NSE: CADBURY I Bloomberg: CADBURY: NL I Reuters: CADBURY: LG



April 22, 2021

## **Analyst's Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

**Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

## **Investment Ratings**

#### Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

#### **Ratings Specification**

**BUY:** Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

**SELL:** Target Price of the stock is more than **10 percent** below the current market price.

#### **Definitions**

**Price Targets:** Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.



April 22, 2021

**Asset allocation:** The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

## **Movements in Price Target**

Company Name: Cadbury Nigeria Plc.

Date	Price (N)	Previous Target Price(N)	New Target Price (N)	Previous Recommendation	New Recommendation
22-Apr-2021	7.80	N/A	8.16	N/A	HOLD

## **Company disclosures**

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

D
Disclosure

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



April 22, 2021

### **Conflict of Interest**

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

### **Important Disclosure**

**For U.S. persons only:** This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

#### Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2021 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.